Skip to main content
. 2015 Mar 11;2015:926168. doi: 10.1155/2015/926168

Table 2.

Overall secondary endpoints.

Tacrolimus (n = 168) Sirolimus (n = 29)
Progression to RRT, n (%) 0 0
Biopsy-proven acute cellular rejection, n (%) 24 (14)b 10 (34)b
Graft survival 1 year after transplant, % 90.7c 82.6c
Patient survival 1 year after transplant, % 95.6b,c 84.8b,c

aOutlier detected using Grubb's test.

b P < 0.05 between treatment groups.

cSurvival analysis: n = 182 for tacrolimus group and n = 46 for sirolimus group.